TScan Therapeutics

IPO

Engineering Immunity

Public · Waltham, United States · Founded 2018 · $190.0M raised

Employees
51–200
Founded
2018
Business Model
B2B
Total Funding
$190.0M
Last Round
$30.0M Corporate RoundDec 2024
Rounds
4
Type
Public

About

TScan Therapeutics is a fully integrated clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for patients with cancer and autoimmune disorders. Founded in 2018, its lead candidate TSC-101 targets AML and MDS patients undergoing allogeneic transplant, with a Phase 3 trial expected in 2026.

Summary

TScan Therapeutics is a Biotech company based in Waltham, United States, founded in 2018. It has raised $190.0M in total across 4 rounds, most recently a $30.0M Corporate Round round in Dec 2024. Investors include Lynx1 Capital Management, BlackRock and RA Capital Management.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Corporate RoundCorporate RoundDec 2024
$30.0M

Sign up to see all 6 rounds

Series A through Corporate Round — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

TScan Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/tscan-therapeutics"><img src="https://indexed.vc/api/badge/company/tscan-therapeutics" alt="TScan Therapeutics on Indexed.vc" width="260" height="76" /></a>